Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: recombinant protein factor V - Leiden/Cambridge

Next Previous
X
Search
Drug Profile

Research programme: recombinant protein factor V - Leiden/Cambridge

Alternative Names: Recombinant protein factor V - Leiden/Cambridge

Latest Information Update: 30 May 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crucell
  • Class Recombinant proteins
  • Mechanism of Action Factor V stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haemophilia A

Most Recent Events

  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
  • 16 Nov 2006 Preclinical trials in Haemophilia A in Netherlands (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top